---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003868"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:24:20.512027+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Setrusumab OI trials on track; alvelestat FDA alignment; leflutrozole licensed for up to $64.25M

## Summary
- Setrusumab: Phase 3 Orbit study (195 patients) expected full enrollment around end Q1 2024; Cosmic study (~65 patients) expected full enrollment 1H 2024.
- Phase 2 data showed 67% reduction in annualized fracture rate; additional data expected 2024.
- Alvelestat: FDA aligned on Phase 3 design with SGRQ Total Score as primary endpoint; could support full U.S. approval.
- Leflutrozole: global license deal with ReproNovo; Mereo received upfront payment and up to $64.25M in milestones plus tiered royalties.
- Cash runway guidance reaffirmed: existing cash expected to fund operations into 2026.

## SEC filing metadata
- accession: 0001193125-24-003868
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312524003868/0001193125-24-003868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312524003868/d100759d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003868
- JSON: https://secwatch.observer/filing/0001193125-24-003868.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.